New drug delivery - Enhanced stability & bioavailability of poorly soluble APIs

DATE
June 16, 2021
TIME
8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST Duration: 60 Minutes

Overview

Imagine what you could do if working with poorly soluble (BCS2) compounds was not an insurmountable issue. BCS2 compounds account for 40% of the APIs on the market today, however, 70-80% of pharmaceuticals active in the pipeline have been shelved due to solubility issues.

Grace experts will detail new ways silica drug delivery technology is giving pharmaceutical manufacturers a new drug delivery option to improve solubility and bioavailability by improving the physical and chemical stability in pharmaceutical APIs.

Brought to you by:
W. R. Grace & Co.

Speakers

Chintan Shah
Lead Manager, Technical and Customer Service (TCS),
Pharma and Nutrition,
W. R. Grace & Co.
Jeff Huber
Technical Contributing Editor,
C&EN Media Group

Registration

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) via email, in accordance with the ACS Privacy Policy.

© 2024 American Chemical Society, 1155 16th St NW, Washington, DC 20036, USA. View our Privacy Policy